Table V.

Induction of Melan-A-specific and tumor-reactive CTL by in vitro stimulation with Melan-A peptide analog

PatientE/TbPercentage Specific Lysis from Cultures Stimulated with Peptidea
Melan-A27–35Melan-A26–35Melan-A25–35A27L
T2T2 +M10Me260Me290T2T2 +M10Me 260Me 290T2T2 +M10Me 260Me 290
LAU 20310038c29717374115632 83 1881
30291110017237126 96 475
1036209170017 73 162
LAU 1321009121019196334 50 631
3037205101216 32 318
10005100105 23 26
LAU 14510015244139405929 50 630
309123115252110 29 519
1036004600101637
LAU 8610036292254438141035452415
301715952026602423104
101652010101014910
LAU 501002126751820551926620
307164581310101838
107704041031200
LAU 1481005139134464590343994
3019854202612192793
10361014146013130
LAU 16110024226133313125 38 423
3038611612301823213
102050972051134
LAU 119100312751233311418 46 545
307131117233413 39 425
104000912107 17 216
Clone 6d107 78 2 63
33 74 0 61
10 65 0 51
  • a Lytic activity was assayed 7 days after the third restimulation with the indicated Melan-A peptide.

  • b Lymphocyte to target cell ratio titration was performed for every culture.

  • c Numbers represent the percentage specific lysis obtained for each target. Me 290 is a Melan-A and HLA-A*0201-positive melanoma cell line obtained from patient LAU 203. Me 260 is a HLA-A*0201 negative melanoma cell line obtained from patient LAU 149. Each number represents the geometric mean of duplicate cultures. Numbers in bold face type indicate significant specific CTL activity, when the differences in specific lysis obtained on T2 cells in presence or in absence of Melan-A26–35 (1 μM) (abbreviated as M10) and on Me 290 or Me 260 are equal or higher than 10%.

  • d Clone 6 is a Melan-A-specific CTL clone derived from the TILN LAU 132, used as positive control.